Opioid Use Disorder Market Size to Exceed USD 6.87 Bn by 2032

The Opioid Use Disorder Market, estimated at USD 3.83 Bn in 2025, is expected to exhibit a CAGR of 8.7% and reach USD 6.87 Bn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Key market players are focusing on adoption of growth strategies such as launch of new products, and this is expected to drive the global opioid use disorder market growth. For instance, in March 2020, Dr. Reddy's Laboratories, a pharmaceutical company,  launched naloxone hydrochloride injection USP, 2 mg/2 mL (1 mg/mL) single-dose prefilled syringe.

Global Opioid Use Disorder Market – Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems regarding transportation of things from one place to another.

However, the COVID-19 pandemic had negative impact on the global opioid use disorder market, as patients with opioid use disorder had limited access to opioid treatment programs during the COVID-19 public health emergency, whereas access to buprenorphine, an opioid drug treatment, remained undisrupted. For instance, on July 28, 2022, according to the report published by the National Center for Biotechnology Information, the U.S. National Library of Medicine reported that the proportion of patients reaching 90-day retention on buprenorphine treatment decreased significantly from 49.6% to 47.7% in the U.S. in 2020 during the COVID-19 pandemic. Moreover, the supply and distribution of drugs was negatively impacted due to the COVID-19 lockdown and restrictions. For instance, in June 2021, according to an article published by United Nations Office on Drugs and Crime (UNODC), a United Nations office, the distribution of naloxone was negatively affected in about 57%of countries. However, according to the same source, regulatory authorities in several regions reduced barriers to access certain medicines, by permitting greater use of telehealth services for drugs such as naloxone, methadone, or buprenorphine.

Global Opioid Use Disorder Market : Key Developments

On May 23, 2023, Braeburn Inc.,  company that provides solutions for people living with the serious consequences of opioid use disorder, announced that the U.S. Food and Drug Administration (FDA) had approved BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), a medication for moderate to severe opioid use disorder (OUD) in patients. BRIXADI can be used as part of a complete treatment plan that includes counseling and psychosocial support.

On October 25, 2022, IntelGenx Corp., a biotechnology company, announced that its, buprenorphine buccal film, for which an abbreviated new drug application had been filed by Chemo Research SL and Xiromed LLC, a vertically integrated generic company, had received the U.S. Food and Drug Administration Generic Drug User Fee Act on April 28, 2023. Buprenorphine buccal film is a generic version of belbuca, an opioid that is used to managepain severe opioids disorders

In December 2021, Emplicure AB, a pharmaceutical company, signed an agreement with Quotient Sciences, a U.K.-based global drug development and manufacturing company. The Quotient Sciences  manufactures EMPLI03 that is used as an opioid buprenorphine to treat chronic pain. Under the terms of this agreement, Quotient Sciences will perform first pharmacokinetic study. This will assist the manufacturing portfolio of EMPLI03 for GMP manufacturing for the clinical study.

In December 2020, BayMark Health Services, a provider of health care services, acquired Choices of Louisiana, an opioid treatment company that consists of three opioid treatment programs (OTPs), one in Alexandria and two in the New Orleans, LA market, U.S.The programs provide medication-assisted treatment (MAT) for opioid addictions supported by substance use counseling. The company provides services under the BayMark brand BAART Programs, which operates a location in Breaux Bridge, Louisiana. The programs are medication-based

In October 2020, Hikma Pharmaceuticals PLC., a multinational pharmaceutical company, and Arecor Limited, a biopharmaceutical company advancing therapies, announced that both companies had entered into a new agreement to co-develop a ready-to-administer injectable medicine in U.S., through Hikma’s affiliate Hikma Pharmaceuticals USA Inc.

Browse 35 Market Data Tables and 31 Figures spread through 174 Pages and in-depth TOC on “Global Opioid Use Disorder Market ”- Forecast to 2030, Global Opioid Use Disorder Market, By Drug Type (Buprenorphine, Methadone, Naltrexone, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/opioid-use-disorder-market-4597

Key Takeaways of the Global Opioid Use Disorder Market :

• Global opioid use disorder market is expected to exhibit a CAGR of 8.7% during the forecast period, owing to rising awareness by government authorities for preventing drug overdose deaths in the U.S, and this is expected to drive growth of the market during the forecast period. For instance, on October 27, 2021, the Centers for Disease Control and Prevention (CDC) launched four educational projects aimed for young adults aged 18 to 34 years old. The campaigns educated people about fentanyl's prevalence and hazards, the perils and repercussions of mixing drugs, the life-saving power of naloxone, and the necessity of decreasing stigma around drug use in order to help people recover. Naloxone is available in all 50 states of the U.S., and it is available at many local pharmacies without a prescription in most states.
• Among route of administration, the parenteral segment is expected to hold a dominant position in the global opioid use disorder market during the forecast period owing to increasing organic growth strategies such as product approval by regulatory authorities to expand product portfolio of the key market players. For instance, on October 19, 2021, Healio, a manufacturer of pharmaceuticals, announced that U.S. Food and Drug Administration had approved Zimhi (naloxone hydrochloride) to be delivered as a high dose of 5 mg/0.5 mL, either intramuscularly or subcutaneously. The U.S. FDA approved Zimhi, a high-dose naloxone product that is administered through a prefilled syringe to counteract potentially fatal opioid overdoses. The approval  based on the CDC data indicated 70.6% of the 70,630 drug overdose deaths in the U.S. in between 2019 to 2021. In 2021, according to the provisional data published by CDC, over 99,000 Americans w died from drug overdoses during the march 2019 to March 2021.
• Among region, North America is expected to be the dominant region in the global opioid use disorder market, owing to increasing incidence of overdose of drug addicted patients in the region is expected to drive the market growth over the forecast period. On December 17, 2020, according to recent provisional data published by the Centers for Disease Control and Prevention (CDC), over 81,000 drug overdose deaths occurred in the U.S. in May 2020, the highest number of overdose deaths ever recorded in a 12-month period.
• Major players operating in the global opioid use disorder market are Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc, Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Hikma Pharmaceuticals PLC, Camurus AB, Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., Purdue Pharma LP, Alvogen, Faran Shimi Pharmaceutical, Novartis AG, Emplicure AB, MODASA Pharmaceuticals Pvt. Ltd.